AstraZeneca files series of patent lawsuits against potential generic Crestor producers
WILMINGTON, Del. AstraZeneca has filed patent infringement actions against a total of eight drug companies who are trying to get their generic versions of the cholesterol lowering drug Crestor approved for marketing, according to published reports.
The first company that tried to file for a generic version was Cobalt Pharmaceuticals last month. The company submitted an application to market a generic version of Crestor in 5 mg, 10 mg, 20 mg and 40 mg strengths. It alleged that the claims of two patents, which expire in January 2016 and August 2020 “are not infringed, invalid or unenforceable” by its move. AstraZeneca denounced the challenges, stating that it believed strongly in its intellectual property portfolio.
The other companies making patent challenges are Teva Pharmaceuticals, Aurobindo Pharma, Apotex, Par Pharmaceutical, Novartis’ Sandoz unit, Mylan, Glenmark Pharmaceuticals and Sun Pharmaceutical. AstraZeneca is taking action against Aurobindo, Apotex, Cobalt, Par, Sandoz, Mylan and Sun, but not Teva and Glenmark, since they sent notice letters to the drugs giant that they are challenging two patents, expiring in 2020 and 2021, not the 2016 one.
Crestor brought in over $2 billion for the company last year, making it the company’s third best selling product.
FDA grants Mylan tentative approval for generic Lamictal
PITTSBURGH, Pa. Mylan Pharmaceuticals has received tentative approval from the Food and Drug Administration for a generic version of Lamictal.
Lamictal, by GlaxoSmithKline is used to treat epilepsy and bipolar I disorder. The generic version, lamotrigine, will be available in 25 mg, 100 mg, 150 mg and 200 mg tablet strengths.
The drug had sales of about $1.97 billion for the 12 months ended Sept. 30, 2007.
NoMoreClipboard.com, ReliefInsite.com partner to offer online pain management module
FORT WAYNE, Ind. NoMoreClipboard.com and ReliefInsite.com have teamed up to ease pain management for patients, practitioners and caregivers. The two have incorporated a free pain management module into the NoMoreClipBoard.com interface.
NoMoreClipboard.com, an online personal health record company, works with health care providers and industry groups to simplify transactions between patients, providers and payors, saving each party significant time and effort. Within NoMoreClipboard.com, patients or caregivers can store information such as allergies, medications and medical conditions in a secure environment. The patient can then choose to share their records with selected health care providers, and NoMoreClipboard.com takes care of securely transferring the record to physicians on behalf of the patient. ReliefInsite.com is a health care information technology company that provides secure online pain management services.
The ReliefInsite.com pain management module within NoMoreClipboard.com allows patients to share their daily pain diary with doctors, nurses, therapists, family members and friends. In addition, ReliefInsite.com offers dynamic, real-time graphical reports to help improve patient compliance, and assists case managers by monitoring therapy effectiveness with time-stamped records, revealing the interaction between pain levels and the patient’s personal and professional lifestyle.
“NoMoreClipboard.com allows patients to store and manage health information and share it with their health care providers, easily and seamlessly,” said Jeff Donnell, NoMoreClipboard.com vice president of marketing. “The ReliefInsite pain management module makes our personal health record even more valuable for the 50 million Americans who currently suffer from chronic pain.”